Sunil Mistry
Clinical Research Lead at Compass Pathways
Data updated
Papers
Trials
Research Footprint
Sunil Mistry appears in 7 tracked papers (2022–2025), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Lindsey Marwood and Ekaterina Malievskaia.
Background & Research
Sunil Mistry appears to be a clinical research professional associated with Compass Pathways, contributing to the company’s psilocybin clinical program. He is listed as an author on several papers covering treatment-resistant depression, antidepressant discontinuation, long-term follow-up, and a healthy-participant phase 1 trial.
Key Impact
He is an author on multiple Compass Pathways psilocybin studies spanning healthy-volunteer, depression, SSRI-concomitant, and follow-up research.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Sunil Mistry is associated with.